Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Cannabis Bioscience International Holdings, Inc.
- Market Cap
- Unavailable
- Price
- $0.0001
- % Change (Daily % change from the live per-ticker quote feed.)
- -33.33%
- Volume
- 500
About
China Infrastructure Construction Corp. delivers specialized education focusing on medical cannabis to audiences in the United States and Latin America, while also reaching a global market through its online programs. The company further extends its services to therapeutic areas, including supporting clinical trials and offering focused treatment for sleep disorders, specifically those linked to infertility, all managed through its fertility and sleep center located in Houston, Texas. Its Pharmacology University division broadens this scope by providing consulting, digital publishing, marketing, and franchising opportunities, alongside additional educational content related to medical cannabis. Founded in 2003, the organization's main operational hub is situated in Houston, Texas.
Quick stats
Shares outstanding—
Computed float4.8B
Float / sharesUnknown
Key info
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001411057
Websitehttps://www.cbih.net
AI Summary
AI-generated1/12
minorneutraloperations update
CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research
CBIH announced the development of an intranasal nanoemulsion platform aimed at exploring cannabinoid-based treatments for Alzheimer's disease.
The technology is designed to deliver neuroactive compounds across multiple pathways rather than targeting a single biological mechanism.
Management cited the growing burden of Alzheimer's, with costs estimated at $409 billion in 2026, as a driver for this research initiative.
Red flags
- Technology in pre-research stage with no clinical data or regulatory submissions disclosed